DK1660115T3 - Farmaceutisk kombination af G-CSF og PLGF anvendelig til blodstamceller - Google Patents

Farmaceutisk kombination af G-CSF og PLGF anvendelig til blodstamceller

Info

Publication number
DK1660115T3
DK1660115T3 DK04763431.6T DK04763431T DK1660115T3 DK 1660115 T3 DK1660115 T3 DK 1660115T3 DK 04763431 T DK04763431 T DK 04763431T DK 1660115 T3 DK1660115 T3 DK 1660115T3
Authority
DK
Denmark
Prior art keywords
csf
useful
stem cells
plgf
blood stem
Prior art date
Application number
DK04763431.6T
Other languages
English (en)
Inventor
Alessandro Massimo Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Application granted granted Critical
Publication of DK1660115T3 publication Critical patent/DK1660115T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04763431.6T 2003-07-29 2004-07-23 Farmaceutisk kombination af G-CSF og PLGF anvendelig til blodstamceller DK1660115T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017174 2003-07-29
PCT/EP2004/008245 WO2005014023A1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell

Publications (1)

Publication Number Publication Date
DK1660115T3 true DK1660115T3 (da) 2011-10-10

Family

ID=34130041

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04763431.6T DK1660115T3 (da) 2003-07-29 2004-07-23 Farmaceutisk kombination af G-CSF og PLGF anvendelig til blodstamceller

Country Status (21)

Country Link
US (1) US20070036747A1 (da)
EP (1) EP1660115B1 (da)
JP (1) JP4855253B2 (da)
KR (1) KR101192136B1 (da)
CN (1) CN100534528C (da)
AT (1) ATE513555T1 (da)
AU (1) AU2004262909B2 (da)
BR (1) BRPI0412989A (da)
CA (1) CA2526244C (da)
DK (1) DK1660115T3 (da)
ES (1) ES2369487T3 (da)
IL (1) IL173369A (da)
MX (1) MXPA06000017A (da)
NO (1) NO20060955L (da)
NZ (1) NZ543612A (da)
PL (1) PL1660115T3 (da)
PT (1) PT1660115E (da)
RU (1) RU2351357C2 (da)
SI (1) SI1660115T1 (da)
WO (1) WO2005014023A1 (da)
ZA (1) ZA200509361B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2206719E (pt) 2005-03-02 2015-02-05 Univ Maryland Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
BR112012002797A2 (pt) 2009-08-07 2019-09-24 Tokai Pharmaceuticals Inc tratamento de câncer de próstata
KR20160023638A (ko) 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
CN114891746A (zh) * 2021-12-21 2022-08-12 青岛今墨堂生物技术有限公司 一种犬全血造血干细胞的制备方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
EP1147777A1 (en) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
KR20030034177A (ko) * 2000-09-13 2003-05-01 쥬가이 세이야쿠 가부시키가이샤 허혈성 질환 치료제
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
EP1594527A2 (en) * 2003-02-04 2005-11-16 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells

Also Published As

Publication number Publication date
MXPA06000017A (es) 2006-03-21
JP2007500157A (ja) 2007-01-11
ZA200509361B (en) 2007-03-28
RU2006106228A (ru) 2007-09-10
NZ543612A (en) 2008-03-28
KR20060079753A (ko) 2006-07-06
PL1660115T3 (pl) 2011-11-30
CN1826134A (zh) 2006-08-30
NO20060955L (no) 2006-02-27
IL173369A (en) 2010-12-30
ES2369487T3 (es) 2011-12-01
SI1660115T1 (sl) 2011-10-28
EP1660115A1 (en) 2006-05-31
BRPI0412989A (pt) 2006-10-03
EP1660115B1 (en) 2011-06-22
JP4855253B2 (ja) 2012-01-18
AU2004262909A1 (en) 2005-02-17
RU2351357C2 (ru) 2009-04-10
CA2526244A1 (en) 2005-02-17
WO2005014023A1 (en) 2005-02-17
KR101192136B1 (ko) 2012-10-16
PT1660115E (pt) 2011-08-24
CN100534528C (zh) 2009-09-02
CA2526244C (en) 2012-03-20
AU2004262909B2 (en) 2010-07-01
US20070036747A1 (en) 2007-02-15
ATE513555T1 (de) 2011-07-15
IL173369A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20063430L (no) Generelt lineaer, brusende oral fentanyl doseringsform, og metoder for administrering
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20054244D0 (no) Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
DK1730131T3 (da) Glucopyranosyl-substituerede benzol-derivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
NO20064584L (no) Tetrahydropyridoindolderivater
SE0301653D0 (sv) Novel compounds
TR200100054T2 (tr) Paroksetin metansülfonat
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
DK2076588T3 (da) Ekspansionsfremgangsmåde til voksne stamceller fra blod, især perifert blod, og dermed forbundet anvendelse på det medicinske område
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
DK1558612T3 (da) Imidazopyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK2083007T3 (da) Tiotropiumsalte, fremgangsmåder til deres fremstilling og lægemiddelformuleringer indeholdende disse
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir